

30<sup>th</sup> May 2017

To,  
**Manager - DSC**  
BSE Limited,  
Floor 25, P J Towers,  
Dalal Street, Mumbai – 400 001

**Subject:** Outcome of Board Meeting & Submission of Audited Financial Results for Half Year and Year ended March 31, 2017.

**Ref.: Scrip Code: 536456**

**Scrip ID: RJBIOTECH**

Dear Sir,

As per Regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing here with Audited Financial Results of the Company for the Half Year and Year ended March 31, 2017, along with the Statement of Impact of Audit qualifications for the Standalone Financial Results duly approved by Board of Directors of the Company at its meeting held on 30<sup>th</sup> May, 2017.

The meeting commenced at 3.00 P.M. and was concluded at 5.00 P.M

We request you to kindly take the same on record.

Thank you,  
Yours Truly,

**FOR R J BIO-TECH LIMITED**

  
**NEHA AGRAWAL**  
(Company Secretary)





**INDEPENDENT AUDITOR'S REPORT**

To,  
The Board of Directors of  
R J Bio-Tech Limited.  
"Siddharth Arcade", Opp. Holiday Camp, Station Road,  
Aurangabad - 431 005


We have audited the Half Yearly financial results of R J Bio-Tech Limited ("The Company") (Formerly known as R J Bio-Tech Private Limited) for the Half Year ended as on 31.03.2017 and the year to date results for the period 01.04.2016 to 31.03.2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Half Yearly financial results as well as the year to date financial results have been prepared on the basis of the Half Yearly & Annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such Half Yearly & Annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Half Yearly & Annual Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

**Basis for Disclaimer of Opinion**

- i) As per the information & explanations given, management has sent balance confirmations to outstanding debtors, due to ongoing season, confirmations are still awaited. In the absence of unavailability of confirmations we are unable to confirm or verify by alternative means accounts receivable included in the Balance Sheet at a total amount of Rs.21,08,43,295/- (before provision for bad & doubtful debts of Rs. 210,84,300/-) as at March 31, 2017.

As a result of this matter, we were unable to determine whether any adjustments might have been found necessary in respect of recorded receivables in the Balance Sheet, and the corresponding elements making up the Statement of Profit and Loss and Cash Flow Statement.







### Disclaimer of Opinion

In our opinion and to the best of our information and according to the explanations given to us these Half Yearly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) Except for the effects of the matter described in Basis for Disclaimer of Opinion paragraph, the financial statement give the information required by the act in the manner so required and give a true and fair view of the net profit/ loss and other financial information for the Half Year ended 31.03.17 as well as the year to date results for the period from 01.04.2016 to 31.03.2017.

For Ashok Patil & Associates  
Chartered Accountants  
Firm Reg. No. 122045W



( Ashok P. Patil )  
Partner  
M.No. 34423


Place: Aurangabad  
Date : 30.05.2017

**Audited Statement of Assets and Liabilities as on 31<sup>st</sup> March, 2017**

Particulars	(Rs. in Lakhs)	
	As on 31-03-2017	As on 31-03-2016
<b>I] EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	148.54	1,650.24
(c) Money received against share warrants	-	-
<b>(2) Share Application money pending allotment</b>	-	-
<b>(3) Non-Current Liabilities</b>		
(a) Long-term Borrowings	146.50	4.05
(b) Deffered Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	84.71	100.82
(d) Long-term Provisions	-	-
<b>(4) Current Liabilities</b>		
(a) Short-Term Borrowings	2,756.67	2,441.34
(b) Trade Payables	186.69	248.10
(c) Other Current Liabilities	422.77	540.29
(d) Short-Term Provisions	60.52	57.48
<b>TOTAL</b>	<b>4,753.15</b>	<b>5,989.08</b>
<b>II] ASSETS</b>		
<b>(1) Non Current Assets</b>		
(a) Fixed Assets		
(i) Tangible Assets	195.23	211.82
(ii) Intangible Assets	0.05	0.09
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
(b) Non-Current Investments	-	-
(c) Deffered tax Assets (Net)	-	-
(d) Long-term loans & Advances	32.64	32.76
(e) Other non-Current assets	174.72	217.29
<b>(2) Current Assets</b>		
(a) Current Investments	-	-
(b) Inventories	2,352.33	2,971.03
(c) Trade Receivables	1,897.59	2,391.70
(d) Cash & Cash equivalents	3.74	(0.76)
(e) Short-term loans and advances	75.97	145.22
(f) Other current assets	20.87	19.94
<b>TOTAL</b>	<b>4,753.15</b>	<b>5,989.08</b>

**Note:**

01. The Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30.05.2017
02. There were no Investor Complaints received / pending as on 31/03/2017.
03. The Company does not have more than one reportable primary segment in terms of Accounting Standard 17 ( AS 17 - Segment Reporting) issued by ICAI/Company (Accounting Standards) Rules, 2006. Therefore, the Company is not required to submit separate segment wise report.
04. Figures of the previous have been re-grouped / re-arranged wherever considered necessary.



For & on Behalf of the Board of Directors of  
R J BIO-TECH LIMITED

(Raghavendra Joshi )  
Director  
DIN No.: 00307124

Place: Aurangabad  
Date : 30.05.2017



Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111  
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

### Audited Financial Results for the period ended 31<sup>st</sup> Mar. 2017

(Rs. in Lakhs)

Sr. No.	Particulars	Half year ended	Preceding Half year ended	Corresponding Half year ended	Year to date figure for current period ended	Year to date figures for the previous year ended	Previous year ended
		31.03.2017	30.09.2016	31.03.2016	31.03.2017	31.03.2016	31.03.2016
		Audited	Unaudited	Audited	Audited	Audited	Audited
01.	Income						
	Net Sales / Income From Operations (Net of excise duty) (Refer Note No.1)	9.47	1,564.37	975.59	1,573.83	3,595.88	3,595.88
	Other Operating Income	-	-	-	-	-	-
	Total Income From Operations (net)	9.47	1,564.37	975.59	1,573.83	3,595.88	3,595.88
02.	Expenditure						
a.	Cost of material consumed (Refer Note No. 2)	287.69	746.52	451.02	1,034.20	1,641.78	1,641.78
b.	Purchase of stock in trade	-	-	-	-	-	-
c.	Change in inventories of finished goods, work in progress and stock in trade (Refer Note No. 3)	274.79	(62.60)	(61.71)	212.20	(225.01)	(225.01)
d.	Employee benefit expenses	64.55	69.20	94.54	133.75	198.91	198.91
e.	Depreciation and amortization expenses	14.97	16.84	22.35	31.81	43.59	43.59
f.	Other expenses - (Refer Note No. 4)	454.92	854.25	531.34	1,309.17	1,364.79	1,364.79
	Total Expenses	1,096.92	1,624.22	1,037.55	2,721.14	3,024.05	3,024.05
03.	Profit/(loss) from Operations before Other Income, finance cost & Exceptional Items (1-2)	(1,087.46)	(59.85)	(61.96)	(1,147.30)	571.83	571.83
04.	Other Income	-	-	-	-	-	-
05.	Profit/(loss) before finance cost & exceptional items (3+4)	(1,087.46)	(59.85)	(61.96)	(1,147.30)	571.83	571.83
06.	Finance cost	194.07	166.02	175.42	360.09	343.73	343.73
07.	Profit/(loss) from ordinary activities after finance cost but before exceptional items (5+6)	(1,281.53)	(225.87)	(237.38)	(1,507.40)	228.10	228.10
08.	Exceptional Items	(0.04)	5.75	-	5.71	-	-
09.	Profit / (Loss) from Ordinary activities before tax (7+8)	(1,281.57)	(220.12)	(237.38)	(1,501.69)	228.10	228.10
10.	Tax Expenses	0.01	-	1.17	0.01	1.17	1.17
11.	Net Profit / (Loss) from Ordinary activities after tax (9-10)	(1,281.59)	(220.12)	(238.55)	(1,501.70)	226.93	226.93
12.	Extraordinary Item (net of tax expenses -- lakhs)	-	-	-	-	-	-



*Handwritten signature*



13.	Net Profit / (Loss) for the Period (11+12)	(1,281.59)	(220.12)	(238.55)	(1,501.70)	226.93	226.93
14.	Share of profit /(loss) of associates	-	-	-	-	-	-
15.	Minority Interest	-	-	-	-	-	-
16.	Net profit/(loss) after taxes, minority interest and share of profit (loss) of associates (13+14+15)	(1,281.59)	(220.12)	(238.55)	(1,501.70)	226.93	226.93
17.	Paid up share capital (face value of share Rs. 10/-)	946.76	946.76	946.76	946.76	946.76	946.76
18.	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	847.57	1,430.13	1,650.24	148.54	1,650.24	1,650.24
19i	(a) Basic & diluted EPS before Extraordinary items for the Period, for the year to date & for the previous year (not to be annualized)	(27.15)	(2.32)	(5.03)	(15.86)	2.40	2.40
19ii	(b) Basic & diluted EPS after Extraordinary items for the Period, for the year to date & for the previous year (not to be annualized)	(27.15)	(2.32)	(5.03)	(15.86)	2.40	2.40

**Note No. 1 - Reconciliation of Sales**

Particulars	Amount ( Rs. In Lacs)
Gross Sales for the period from Oct 16 to Mar 17	389.9
Less : Sales Return corresponding to previous period	(380.43)
Net Sales	9.47

**Note No. 2 - Reasons for increase in Cost of Raw Materials Consumed :-**

During the period from October 16 to March 17, some of the Lots of unprocessed seeds has failed in the test of "Germination" or "Grow out test" (Laboratory Testing) due to the losses in seed quality occurred during field weathering, harvesting and storage. These seeds were not usable for further processing hence the value of these seeds has been written off which has resulted in increased consumption

**Note No. 3 - Reasons for decrease in value of Finished Goods Inventory :-**

Company has received Processed Seeds in the form of Sales Return from customers due to quality deterioration in the seeds. As the quality of the returned seeds is already detracted, it was not usable for the further processing hence management has written off the seeds value of these returned seeds which have impacted on the decrease in the value of Finished Goods ( Processed Seeds).

**Note No. 4 - Reasons for increase in other costs :-**

Management has decided to made provision for Bad & Doubtful debts of Rs. 210,84,300/- which is 10% value of the total debtors. This provision has impact on increase in the other expenses of the company by Rs. 210,84,300/-.

Place: Aurangabad  
Date : 30.05.2017



For & on Behalf of the Board of Directors of  
R J BIO-TECH LIMITED


(Raghavendra Joshi)  
Director  
DIN No.: 00307124



**ANNEXURE I**

**Statement on Impact of Audit Qualifications (for audit report with modified opinion) submitted along-with Standalone Annual Audited Financial Results**

<b><u>Statement on Impact of Audit Qualifications for the Financial Year ended March 31, 2017</u></b> <b><u>[See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]</u></b>				
I	Sl. No.	Particulars	Audited Figures (as reported before adjusting for qualifications) (Rs. In Lacs)	Adjusted Figures (audited figures after adjusting for qualifications) (Rs. In Lacs)
	1.	Turnover / Total income	1573.83	1573.83
	2.	Total Expenditure	3081.23	3081.23
	3.	Net Profit/(Loss)	(1501.70)	(1501.70)
	4.	Earnings Per Share ( In Rs.)	(15.86)	(15.86)
	5.	Total Assets	4753.15	4753.15
	6.	Total Liabilities	4753.15	4753.15
	7.	Net Worth	1084.10	1084.10
	8.	Any other financial item(s) (as felt appropriate by the management)	-	-
II.	<b>Audit Qualification (each audit qualification separately):</b>			
	a.	<b>Details of Audit Qualification:</b> As per the information & explanations given, management has sent balance confirmations to outstanding debtors, due to ongoing season, confirmations are still awaited. In the absence of unavailability of confirmations we are unable to confirm or verify by alternative means accounts receivable included in the Balance Sheet at a total amount of Rs.21,08,43,295/- (before provision for bad & doubtful debts of Rs. 210,84,300/-) as at March 31, 2017. As a result of this matter, we were unable to determine whether any adjustments might have been found necessary in respect of recorded receivables in the Balance Sheet, and the corresponding elements making up the Statement of Profit and Loss and Cash Flow Statement.		
	b.	<b>Type of Audit Qualification :</b> <del>Qualified Opinion</del> / Disclaimer of Opinion / Adverse Opinion		
	c.	<b>Frequency of qualification:</b> Whether appeared first time / repetitive / since how long continuing		
	d.	<b>For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views:</b> Nil		
	e.	<b>For Audit Qualification(s) where the impact is not quantified by the auditor:</b>		
	(i)	<b>Management's estimation on the impact of audit qualification: Nil</b> The Company had taken due efforts to provide the confirmation of outstanding balances from all its debtors. Management has already sent balance confirmations to outstanding debtors but due to ongoing season, the Company could not get their confirmations well in time, confirmations are still awaited and as a matter of safety Company has made the provision of 10% for the Doubtful Debts for the Current Financial Year		
	(ii)	<b>If management is unable to estimate the impact, reasons for the same: Nil</b>		
	(iii)	<b>Auditors' Comments on (i) or (ii) above:</b> Already stated in point (II) Auditors Qualification		






Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111  
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

Signatories:

For R J Biotech Limited

Raghavendra Joshi  
Chairman



Aarti Pawar  
Chief Financial Officer

For Ashok Patil & Associates  
Chartered Accountants  
Firm Reg. No. 122045W

Ashok P. Patil  
Partner  
M. No. 34423



Balaji Prithviraj Singh  
Audit Committee Chairman

Place: Aurangabad  
Date: 30/05/2017